CIBC Asset Management Inc Has $2.19 Million Stake in Charles River Laboratories International, Inc. $CRL

CIBC Asset Management Inc lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 70.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 10,993 shares of the medical research company’s stock after buying an additional 4,526 shares during the period. CIBC Asset Management Inc’s holdings in Charles River Laboratories International were worth $2,193,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Principal Financial Group Inc. grew its position in shares of Charles River Laboratories International by 84.5% in the 3rd quarter. Principal Financial Group Inc. now owns 104,719 shares of the medical research company’s stock valued at $16,384,000 after purchasing an additional 47,954 shares during the period. Madison Asset Management LLC bought a new stake in shares of Charles River Laboratories International during the third quarter worth $1,935,000. JPMorgan Chase & Co. increased its position in shares of Charles River Laboratories International by 14.5% during the third quarter. JPMorgan Chase & Co. now owns 317,179 shares of the medical research company’s stock worth $49,626,000 after acquiring an additional 40,073 shares in the last quarter. Penserra Capital Management LLC bought a new stake in shares of Charles River Laboratories International during the third quarter worth $533,000. Finally, Gotham Asset Management LLC increased its position in shares of Charles River Laboratories International by 17.3% during the third quarter. Gotham Asset Management LLC now owns 315,755 shares of the medical research company’s stock worth $49,403,000 after acquiring an additional 46,594 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on CRL. Robert W. Baird set a $213.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. CLSA raised shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and increased their price objective for the stock from $167.00 to $219.00 in a research report on Friday, May 29th. TD Cowen lowered their price objective on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, February 20th. UBS Group increased their price objective on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Finally, Barclays increased their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $208.50.

Charles River Laboratories International Stock Up 0.1%

Charles River Laboratories International stock opened at $181.46 on Monday. The company has a market cap of $8.74 billion, a P/E ratio of -48.26, a price-to-earnings-growth ratio of 2.07 and a beta of 1.46. Charles River Laboratories International, Inc. has a 1-year low of $143.06 and a 1-year high of $228.88. The company has a fifty day simple moving average of $171.37 and a 200 day simple moving average of $181.70. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The business had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Research analysts anticipate that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.